- US Firms Hit by Payroll Taxes at Exactly the Wrong Time
- Citi Mortgage Reveals Something the US Treasury Won't
- Fed Sanguine About US Recovery, Worried on Jobs
- Amended Berkshire Filing Reveals No 'Secret' Holdings
- In Time for Holidays: More Gloom and Doom on Economy
- Turkey Day 101: How Well Do You Know Your Bird?
- Privately Held Facebook Creates Dual-Class Stock
- Holiday Guide to This Season's Smartphones
- Six Ways to Boost Your Income in a Big Way
- Citi Mortgage Reveals What Treasury Won't
- S&P to Hit 1,200 by Year-End: Chief Investor
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Facebook's Biggest-Ever Holiday Shopping Season
- Facebook's New Dual Class Structure - Slow Steps to an IPO
- 5 Big Bank Stocks Investors Should Consider: Strategists
- Gambling Drunk, Texting to Live And America's On Sale - Your Emails
- Nov. 24: Unusual Volume Leaders
- NBA D-League On The Rise
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- CNBC Anchor Takes a Sabbatical
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Privately Held Facebook Creates Dual-Class Stock
- NBA D-League On The Rise
- 10 Holiday Cocktail Recipes from Top Mixologists
- GM's Agreement to Sell Saab To Swedish Firm Falls Apart
- On Twitter, Beware False Prophets
- Buyers Look For Bargains At Luxury Condo Auction
- Just In Time for Holidays: More Gloom and Doom on Economy
Text Size 
Corporate actions and clinical trial data were some of the catalysts behind the most actively traded stocks on Monday.
Shares of Internet services firm Yahoo [YHOO
Loading...
()
] moved higher as investor speculated on potential corporate actions. Shares initially moved higher on unconfirmed reports published in an online media newsletter which said CEO Terry Semel could be close to resigning. Yahoo announced Semel's resignation after the close of trading.
CNBC's David Faber reported that Yahoo may be forced to explore strategic alternatives, with potential interested parties including News Corp., AT&T, Time Warner unit AOL, Microsoft and Comcast.
China Medical Technologies [CMED
Loading...
()
] reported solid fourth-quarter earnings on Monday, citing higher sales of diagnostic and tumor therapy systems. The tiny China-based medical device maker also said it expects a sharp rise in 2007 sales.
Graphics chipmaker Nvidia [NVDA
Loading...
()
] saw shares climb after the company said it bought back 3.3 million shares, according to documents filed with the Securities and Exchange Commission. Nvidia said the stock repurchase was part of its ongoing $1.7 billion buyback plan.
Citadel Broadcasting [CDL
Loading...
()
] shares rose after JP Morgan Securities said the radio broadcaster's recent acquisition of ABC Radio Holdings from Walt Disney [DIS
Loading...
()
] could boost the stock.
"From formerly being a small-market broadcaster with over 80% of its revenues generated in markets smaller than the top 50, the new Citadel will emerge with vastly greater exposure to the largest markets in the country," said analyst John Blackledge.
Genesco [GCO
Loading...
()
] shares gained after smaller rival Finish Line [FINL
Loading...
()
] said it would acquire the company for $1.5 billion, or $54.50 a share.
Genesco had recently rejected a sweetened takeover bid of $1.2 billion from Foot Locker.
Merger speculation for aluminum giant Alcoa [AA
Loading...
()
] continued on Monday after a London newspaper said metal mining titan BHP Billiton [BHP
Loading...
()
] was mulling a potential $40 million bid for Alcoa.
Among downside movers, Encysive Pharmaceuticals [ENCY
Loading...
()
] plunged after the U.S. Food and Drug Administration rejected the company's experimental treatment for high blood pressure in the lungs.
The FDA issued a third "approvable letter" for Thelin and said the drug did not demonstrate the effectiveness needed for approval as a treatment for pulmonary arterial hypertension (PAH) and advised the company to conduct additional clinical studies.
"We believe we adequately addressed the issue raised by the FDA in the second approvable letter and we are deeply disappointed in their decision," Encysive said in a prepared statement.
Encysive said the FDA decision may prompt it to make "significant reductions" in its infrastructure and workforce but will discuss plans at a later date.
The company's announcement comes on the heels of Gilead Sciences' [GILD
Loading...
()
] recent FDA approval of Thelin rival Letairis, which some analysts believe has the potential for blockbuster sales.
Peter Kang is a markets writer at CNBC.com and can be reached at .
Print
Email
- Remember when auto shows were major events where new models could generate buzz?
- CNBC’s Mike Huckman visits a cutting-edge plant to see how the flu vaccine of the future is being made.
- People who bottle up their anger at work are up to five times more likely to suffer a heart attack, a study found.
- Playboy will outsource its publishing operations in a bid to become profitable again.
- A new McDonald's in Manhattan is the nation's first to sport a sleek, chic interior imported from stores in London and Paris.
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
Data is a real-time snapshot *Data is delayed at least 15 minutes